Literature DB >> 7712660

Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline.

C Nordin1, L Bertilsson.   

Abstract

Hydroxymetabolites of the antidepressants nortriptyline and desipramine, like the parent drugs, inhibit neuronal uptake of noradrenaline (norepinephrine). In both plasma and cerebrospinal fluid (CSF), the concentrations of the 10-hydroxymetabolites of nortriptyline (10-OH-NT) are usually higher than those of the parent drugs, but there is a pronounced interindividual variation in the plasma concentrations. This shows that during treatment with nortriptyline, hydroxymetabolites exert, at least in some patients, major effects on brain noradrenaline neurons. Hydroxymetabolites of antidepressants are formed by the polymorphic cytochrome P450 enzyme CYP2D6. Nortriptyline is hydroxylated by this enzyme in a highly stereospecific way to the (-)-enantiomer of E-10-OH-NT. Among Caucasians, 7% are poor metabolisers of the CYP2D6 probe drug debrisoquine. These patients will form very little hydroxymetabolite. The affinity of E-10-OH-NT for muscarinic acetylcholine receptors in vitro was only one-eighteenth of the affinity of nortriptyline for these receptors. In healthy individuals, nortriptyline decreased saliva flow to a significantly greater extent than either E-10-OH-NT or placebo. In an ultrarapid hydroxylator of nortriptyline treated with very high doses of nortriptyline, the plasma concentration of unconjugated 10-OH-NT was very high without any sign of anticholinergic adverse effects. These results show that hydroxymetabolites of nortriptyline have much less anticholinergic effect than the parent drug. When racemic E-10-OH-NT per se was given to healthy individuals, the plasma concentration of the (-)-enantiomer was 5-fold higher than that of (+)-E-10-OH-NT. The 2 enantiomers were eliminated in parallel with an elimination half-life of 8 to 10 hours. A combined in vitro and in vivo investigation showed that a mean of 64% of (+)-E-10-OH-NT was glucuronidated in the liver and subsequently eliminated in urine. Of the administered (-)-enantiomer, a mean of 36% was eliminated as glucuronide formed in the intestine and 35% was actively secreted as unchanged form in urine. Plasma protein binding, determined by ultrafiltration, of the (+)- and (-)-enantiomers of E-10-OH-NT was 54 and 69%, respectively, which is less than that of nortriptyline (92%). The concentration of E-10-OH-NT in CSF was 50% of the concentration of unbound in plasma. There seems to be a stereoselective active transport of E-10-OH-NT from the CSF to blood. We administered racemic E-10-OH-NT to 5 patients during a major depressive episode.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7712660     DOI: 10.2165/00003088-199528010-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  65 in total

1.  Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications.

Authors:  L Bertilsson; B Mellström; F Sjökvist; B Mårtenson; M Asberg
Journal:  Lancet       Date:  1981-03-07       Impact factor: 79.321

2.  Enantioselective formation and disposition of (E)- and (Z)-10-hydroxynortriptyline.

Authors:  E Nusser; K Nill; U Breyer-Pfaff
Journal:  Drug Metab Dispos       Date:  1988 May-Jun       Impact factor: 3.922

3.  Active metabolites of antidepressants: pharmacodynamics and relevant pharmacokinetics.

Authors:  W Z Potter; M V Rudorfer; E A Lane
Journal:  Adv Biochem Psychopharmacol       Date:  1984

Review 4.  Plasma level monitoring of antidepressants: theoretical basis and clinical application.

Authors:  L F Gram; P Kragh-Sørensen; C B Kristensen; M Møller; O L Pedersen; P Thayssen
Journal:  Adv Biochem Psychopharmacol       Date:  1984

5.  The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

Authors:  L Bertilsson; A Aberg-Wistedt
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

6.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

7.  Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity.

Authors:  W Z Potter; H M Calil; A A Manian; A P Zavadil; F K Goodwin
Journal:  Biol Psychiatry       Date:  1979-08       Impact factor: 13.382

8.  Affinity of nortriptyline and its E-10-hydroxy metabolite for muscarinic receptors.

Authors:  L Nilvebrant; C Nordin
Journal:  Pharmacol Toxicol       Date:  1991-01

9.  Determination of clomipramine and its hydroxylated and demethylated metabolites in plasma and urine by liquid chromatography with electrochemical detection.

Authors:  O Spreux-Varoquaux; D Morin; C Advenier; M Pays
Journal:  J Chromatogr       Date:  1987-05-15

10.  Plasma 10-hydroxynortriptyline and therapeutic response in geriatric depression.

Authors:  R C Young; G S Alexopoulos; R Shindledecker; A K Dhar; H Kutt
Journal:  Neuropsychopharmacology       Date:  1988-09       Impact factor: 7.853

View more
  18 in total

Review 1.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

2.  Distribution pattern of mirtazapine and normirtazapine in blood and CSF.

Authors:  Michael Paulzen; Gerhard Gründer; Simone C Tauber; Tanja Veselinovic; Christoph Hiemke; Sarah E Groppe
Journal:  Psychopharmacology (Berl)       Date:  2014-08-23       Impact factor: 4.530

3.  Individual variations of amitriptyline biotransformation examined in scalp hair samples.

Authors:  Detlef Thieme; Dagmar Schmid; Hans Sachs
Journal:  Forensic Sci Med Pathol       Date:  2007-09-06       Impact factor: 2.007

4.  Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.

Authors:  Gisa Gerstenberg; Toshiaki Aoshima; Takashi Fukasawa; Keizo Yoshida; Hitoshi Takahashi; Hisashi Higuchi; Yoshiko Murata; Ritsuko Shimoyama; Tadashi Ohkubo; Tetsuo Shimizu; Koichi Otani
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

Review 5.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

6.  Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms.

Authors:  Detlef Thieme; Burkhard Rolf; Hans Sachs; Dagmar Schmid
Journal:  Int J Legal Med       Date:  2007-11-09       Impact factor: 2.686

7.  The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.

Authors:  Jónrit Halling; Pál Weihe; Kim Brosen
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

Review 8.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Metabolomic biomarkers and novel dietary factors associated with gestational diabetes in China.

Authors:  Xuyang Chen; Jamie V de Seymour; Ting-Li Han; Yinyin Xia; Chang Chen; Ting Zhang; Hua Zhang; Philip N Baker
Journal:  Metabolomics       Date:  2018-11-03       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.